Accessibility Menu
ProMIS Neurosciences logo

ProMIS Neurosciences

(NASDAQ) PMN

Current Price$15.36
Market Cap$28.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-98%
5 Year-94%
1 Year+18%
1 Month+31%
ProMIS Neurosciences last closing stock price
MetricPriceDate
Last closeUSD 13.302026-07-16
ProMIS Neurosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.8%USD 14.272026-07-09
1 month+30.91%USD 10.162026-06-16
3 month+15.35%USD 11.532026-04-17
Year to date+94.87%USD 6.832025-12-31
1 year+18.22%USD 11.252025-07-16
3 year-91.41%USD 154.752023-07-17
5 year-93.89%USD 217.802021-07-16
Since inception-97.79%USD 601.502012-04-16

ProMIS Neurosciences Financials at a Glance

Market Cap

$28.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$40.62M

EPS (TTM)

-$19.41

P/E Ratio

-0.69

Dividend

$0.00

Beta (Volatility)

0.57 (Low)

Price

$15.36

Volume

2,208

Open

$13.37

Previous Close

$15.36

Daily Range

$13.37 - $15.57

52-Week Range

$6.27 - $39.75

Estimated Earnings Date

Aug 12, 2026

PMN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ProMIS Neurosciences

ProMIS Neurosciences develops medicines for brain diseases like Alzheimer’s and ALS. Its main products are experimental antibodies that target harmful proteins in the brain.

These treatments are being developed to help people with memory loss or movement problems by targeting disease-related proteins.

Brainy Business: Products and Services

  • PMN310 (Alzheimer’s): Antibody designed to target toxic amyloid-beta proteins in Alzheimer’s disease. (0% of revenue; no sales)
  • PMN267 (ALS): Antibody aimed at misfolded proteins linked to amyotrophic lateral sclerosis, a progressive nerve disease. (0% of revenue)
  • PMN442 (MSA, Parkinson’s): Antibody for toxic alpha-synuclein proteins in multiple system atrophy and Parkinson’s disease. (0% of revenue)
  • Vaccine Programs: Early-stage vaccines for Alzheimer’s, ALS, and related brain disorders. (0% of revenue)
  • Discovery Platform: Software tools to find new drug targets for brain diseases. (0% of revenue)

Growth and Expansion: The Long and Winding Road

  • Changed name from Amorfix Life Sciences to ProMIS in 2015 to reflect new focus.
  • Launched PRECISE-AD Phase 1b trial for PMN310 in 2025.
  • Received FDA Fast Track status for PMN310 in July 2025.
  • Expanded vaccine and antibody pipeline for neurodegenerative diseases since 2024.
  • Secured exclusive licenses from University of British Columbia for key technology.

What Makes ProMIS Stand Out (Without the Hype)

ProMIS uses computer algorithms to design drugs that only target harmful brain proteins, aiming to avoid side effects. Its approach covers several brain diseases, not just one. The company holds patents on its technology and drug candidates, protecting its research for years.

Five Things You Need to Know

  • No revenue reported for 2023, 2024, or 2025; all products are in development.
  • Operating loss was $40.2 million in 2025, up 139% from 2024.
  • R&D expenses rose 214% to $33.4 million in 2025.
  • Cash used in operations was $28.1 million in 2025, up 3% from 2024.
  • Raised $75.5 million in January 2026 to fund operations through 2027.

Bottom Line

ProMIS focuses on early-stage drug development for brain diseases, with no sales yet. Its future depends on advancing clinical trials and securing more funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

11

CEO

Neil K. Warma, MBA

Website

www.promisneurosciences.com

Headquarters

Toronto, ON M4S 3E2, CA

PMN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-237.99%

Return on Capital

N/A

Return on Assets

-60.25%

Earnings Yield

-1.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$28.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.15M

Volume

2.21K

Avg. Volume

41.22K

Financials (TTM)

Gross Profit

-$9.36M

Operating Income

-$41.35M

EBITDA

-$41.02M

Operating Cash Flow

-$35.47M

Capital Expenditure

$0.00

Free Cash Flow

-$35.47M

Cash & ST Invst.

$63.85M

Total Debt

$0.00

ProMIS Neurosciences Performance Analysis

ProMIS Neurosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
ProMIS Neurosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
ProMIS Neurosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -60.2148.2%
20232023-12-31USD -26.87-55.4%
20242024-12-31USD 2.63N/A
20252025-12-31USD -22.61N/A
ProMIS Neurosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-38.1%
Q32025-09-30-14.1%
Q42025-12-3117.7%
Q12026-03-3181.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$28.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.60M

N/A

Employees

11

N/A

Net Income

-$8.24M

-12.2%

EBITDA

-$8.64M

-17.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$63.85M

+660.3%

Total Debt

$0.00

N/A

Accounts Receivable

$238.33K

+336.8%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-60.25%

N/A

Return on Invested Capital

-68.02%

N/A

Free Cash Flow

-$12.38M

-151.3%

Operating Cash Flow

-$12.38M

-151.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MPLTMapLight Therapeutics, Inc.
$37.87+1.75%
LPCNLipocine Inc.
$2.23-2.62%
OSRHOSR Holdings, Inc.
$0.47-3.79%
BRTXBioRestorative Therapies, Inc.
$0.33-4.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$14.98-0.04%
NOKNokia
$10.12-0.03%
JOBYJoby Aviation
$7.23-0.01%
SOFISoFi Technologies
$17.28-0.00%

Questions About PMN

What is the current price of ProMIS Neurosciences?

ProMIS Neurosciences is trading at $15.36 per share.

What is the 52-week range for ProMIS Neurosciences?

Over the past 52 weeks, ProMIS Neurosciences has traded between $6.27 and $39.75.

How much debt does ProMIS Neurosciences have?

As of the most recent reporting period, ProMIS Neurosciences reported total debt of $0.00.

How much cash does ProMIS Neurosciences have on hand?

ProMIS Neurosciences reported $63.81M in cash and cash equivalents in its most recent financial results.

What is ProMIS Neurosciences’s dividend yield?

ProMIS Neurosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services